Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS COMPLETES FULLY SUBSCRIBED DEBENTURE UNITS FINANCING OF $2,000,000

Defence Therapeutics Inc. has closed its previously announced non-brokered private placement of debenture units at a price of $1,000 per unit for aggregate gross proceeds of $2-million. Each unit consisted of: (i) one $1,000 principal amount 8.0 per cent convertible debenture; and (ii) 1,666 common share purchase warrants. Further to the previous announcement on Aug. 22, 2025, the company has obtained the approval from the Canadian Securities Exchange to upsize the offering from the aggregate proceeds of $1.2-million to $2-million.

The debentures bear interest at a rate of 8.0 per cent per annum and mature on Sept. 15, 2027, subject to early redemption by the company. The debentures are unsecured and rank pari passu in right of payment of principal and interest with all the existing and future unsecured indebtedness of the company. The principal amount of each debenture is convertible at the option of the holder into common shares in the capital of the company at the conversion price of 60 cents per share. The accrued interest of the debentures will be paid annually in shares at the conversion price or in cash at the company's election.

Each warrant is exercisable to acquire one share at an exercise price of 75 cents per warrant share on or before Sept. 15, 2027.

In connection with the offering, the company paid aggregate cash finders' fees totalling $160,000 and issued 266,667 finders' warrants to qualified arm's-length finders. Each finder's warrant is exercisable into one share at an exercise price of 75 cents per finder's warrant share on or before Sept. 15, 2027.

The company intends to use the net proceeds of the offering to advance its science programs and for general working capital. All securities issued in connection with the offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded clinical-stage biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the Accum technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.

We seek Safe Harbor.